Lowest Price Guaranteed
Pages
132
Last Updated
June 2026
View Count
20044
1. BACKGROUND
1.1. Context
1.2. Project Objectives
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control
3. ECONOMIC AND OTHER PROJECT-SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russia-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product (GDP)
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross-Border Dynamics
4.3. Conclusion
5. EXECUTIVE SUMMARY
6. INTRODUCTION
6.1. Overview
6.2. Factors Causing Non-Small Cell Lung Cancer
6.3. Advantages
6.4. Disadvantages
6.5. Future Perspectives
7. MARKET LANDSCAPE: SQUAMOUS NON-SMALL CELL LUNG CANCER DRUGS
7.1. Market Landscape: Squamous Non-Small Cell Lung Cancer Drugs
7.2. Developer Landscape: Squamous Non-Small Cell Lung Cancer Drugs
8. DRUG PROFILES: SQUAMOUS NON-SMALL CELL LUNG CANCER DRUGS
8.1. Chapter Overview
8.2. Detailed Drug Profiles
8.2.1. Necitumumab
8.2.2. Pembrolizumab
8.2.3. Nivolumab
8.2.4. Cemiplimab
8.2.5. Ipilimumab
8.2.6. Atezolizumab
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Partnership Models
9.2. Squamous Non-Small Cell Lung Cancer: Partnerships and Collaborations
9.2.1. Analysis by Year of Partnership
9.2.2. Analysis by Type of Partnership
9.2.3. Analysis by Year and Type of Partnership
9.2.4. Analysis by Target Disease Indication
9.2.5. Analysis by Type of Partner
9.2.6. Most Active Players: Analysis by Number of Partnerships
9.2.7. Local and International Deals
9.2.8. Intercontinental and Intracontinental Deals
10. CLINICAL TRIAL ANALYSIS
10.1. Methodology and Key Parameters
10.2. Squamous Non-Small Cell Lung Cancer Drugs: Clinical Trial Analysis
10.2.1. Analysis by Trial Registration Year
10.2.2. Analysis by Trial Status
10.2.3. Analysis by Trial Registration Year and Trial Status
10.2.4. Analysis by Trial Registration Year and Patients Enrolled
10.2.5. Analysis by Trial Status and Patients Enrolled
10.2.6. Analysis by Trial Phase
10.2.7. Analysis by Patients Enrolled and Trial Phase
10.2.8. Analysis by Study Design
10.2.9. Analysis by Type of Sponsor
10.2.10. Analysis by Patient Gender
10.2.11. Most Active Industry Players: Analysis by Number of Trials
10.2.12. Most Active Non-Industry Players: Analysis by Number of Trials
10.2.13. Analysis by Geography
10.2.13.1. Analysis by Trial Status, Trial Phase and Geography
10.2.13.2. Analysis by Trial Status and Geography
10.2.14. Geographical Distribution of Trials and Number of Patients Enrolled
10.2.14.1. Clinical Trials in North America: Key Insights
10.2.14.2. Clinical Trials in Europe: Key Insights
10.2.14.3. Clinical Trials in Asia-Pacific: Key Insights
10.2.14.4. Clinical Trials in Rest of the World: Key Insights
11. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
11.1. Chapter Overview
11.2. Market Drivers
11.3. Market Restraints
11.4. Market Opportunities
11.5. Market Challenges
12. GLOBAL SQUAMOUS NON-SMALL CELL LUNG CANCER MARKET
12.1. Forecast Methodology and Key Assumptions
12.2. Global Squamous Non-Small Cell Lung Cancer Market, Historical Trends (since 2019) and Forecasted Estimates (till 2035) (USD Billion)
12.2.1. Scenario Analysis
12.2.1.1. Conservative Scenario
12.2.1.2. Optimistic Scenario
12.3. Key Market Segmentations
13. SQUAMOUS NON-SMALL CELL LUNG CANCER MARKET, BY THERAPEUTIC TYPE
13.1. Squamous Non-Small Cell Lung Cancer Market: Distribution by Therapeutic Type
13.1.1. Squamous Non-Small Cell Lung Cancer Market for Immunotherapies, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
13.1.2. Squamous Non-Small Cell Lung Cancer Market for Combination Therapies, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
13.1.3. Squamous Non-Small Cell Lung Cancer Market for Chemotherapy, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
13.1.4. Squamous Non-Small Cell Lung Cancer Market for Targeted Therapies, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
13.1.5. Squamous Non-Small Cell Lung Cancer Market for Radiation Therapies, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
14. SQUAMOUS NON-SMALL CELL LUNG CANCER MARKET, BY DRUG CLASS
14.1. Squamous Non-Small Cell Lung Cancer Market: Distribution by Drug Class
14.1.1. Squamous Non-Small Cell Lung Cancer Market for PD-1 / PD-L1 Inhibitors, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
14.1.2. Squamous Non-Small Cell Lung Cancer Market for Platinum-based Drugs, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
14.1.3. Squamous Non-Small Cell Lung Cancer Market for EGFR Inhibitors, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
14.1.4. Squamous Non-Small Cell Lung Cancer Market for VEGF Inhibitors, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
14.1.5. Squamous Non-Small Cell Lung Cancer Market for ALK Inhibitors, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
15. SQUAMOUS NON-SMALL CELL LUNG CANCER MARKET, BY TREATMENT LINE
15.1. Squamous Non-Small Cell Lung Cancer Market: Distribution by Treatment Line
15.1.1. Squamous Non-Small Cell Lung Cancer Market for First-line Treatment, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
15.1.2. Squamous Non-Small Cell Lung Cancer Market for Second-line Treatment, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
15.1.3. Squamous Non-Small Cell Lung Cancer Market for Adjuvant Therapies, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
15.1.4. Squamous Non-Small Cell Lung Cancer Market for Third-line and Beyond Therapies, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
15.1.5. Squamous Non-Small Cell Lung Cancer Market for Neoadjuvant Therapies, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
16. SQUAMOUS NON-SMALL CELL LUNG CANCER MARKET, BY END-USER
16.1. Squamous Non-Small Cell Lung Cancer Market: Distribution by End-User
16.1.1. Squamous Non-Small Cell Lung Cancer Market for Hospitals, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
16.1.2. Squamous Non-Small Cell Lung Cancer Market for Specialty Clinics, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
16.1.3. Squamous Non-Small Cell Lung Cancer Market for Other End-Users, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
17. SQUAMOUS NON-SMALL CELL LUNG CANCER MARKET, BY GEOGRAPHICAL REGIONS
17.1. Squamous Non-Small Cell Lung Cancer Market: Distribution by Geographical Regions
17.1.1. Squamous Non-Small Cell Lung Cancer Market in North America, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
17.1.2. Squamous Non-Small Cell Lung Cancer Market in Europe, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
17.1.3. Squamous Non-Small Cell Lung Cancer Market in Asia-Pacific, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
17.1.4. Squamous Non-Small Cell Lung Cancer Market in Latin America, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
17.1.5. Squamous Non-Small Cell Lung Cancer Market in Middle East and North Africa, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
18. SQUAMOUS NON-SMALL CELL LUNG CANCER MARKET, SALES FORECAST OF MARKETED AND PHASE III DRUGS
19. EXECUTIVE INSIGHTS
19.1. Chapter Overview
19.2. Company A
19.2.1. Company Snapshot
19.2.2. Interview Transcript: Professor of Medicine and Medical Oncology and Chair in Cancer Research
19.3. Company B
19.3.1. Company Snapshot
19.3.2. Interview Transcript: Co-chair
19.4. Company C
19.4.1. Company Snapshot
19.4.2. Interview Transcript: Surgical Director of the Thoracic Oncology Program, Nurse Practitioner Specializing in Lung Cancer and Professor of Medicine
19.5. Company D
19.5.1. Company Snapshot
19.5.2. Interview Transcript: Thoracic Medical Oncologist & Early Drug Development Specialist
19.6. Company E
19.6.1. Company Snapshot
19.6.2. Interview Transcript: Thoracic Medical Oncologist
19.7. Company F
19.7.1. Company Snapshot
19.7.2. Interview Transcript: Thoracic Medical Oncologist
19.8. Company G
19.8.1. Company Snapshot
19.8.2. Interview Transcript: Medical Oncologist
19.9. Company H
19.9.1. Company Snapshot
19.9.2. Interview Transcript: Co-founder
19.10. Company I
19.10.1. Company Snapshot
19.10.2. Interview Transcript: Pulmonologist and Professor of Medicine
19.11. Company J
19.11.1. Company Snapshot
19.11.2. Interview Transcript: Thoracic Medical Oncologist
20. APPENDIX 1: TABULATED DATA
21. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS